Protenus Granted Sixth Patent for Drug Diversion Surveillance Technology

Date:

New Patent Granted Assists Hospitals With Greater Coverage to Support Drug Diversion Prevention

Protenus, provider of the leading healthcare compliance analytics platform, today announced a new grant of a U.S. patent that supports its ongoing efforts to deliver drug diversion surveillance technology that enables hospitals and health systems to be more efficient and proactively eliminate risk to their organization and patients. 

The new grant of U.S. Patent No. 11,923,062 is titled “Methods and Systems for Analyzing Accessing of Drug Dispensing Systems.” With this patent, Protenus now holds six granted U.S. patents covering various techniques for detecting anomalous drug dispensing events. For example, the newly granted patent covers numerous techniques such as using pattern-based algorithms to identify hidden drug misappropriation events as part of an AI-driven approach.

“Our research estimates that one in 100 healthcare employees are diverting narcotics away from patient care,” states Nick Culbertson, CEO and co-founder of Protenus. He continues, “Our award-winning drug diversion surveillance solution has consistently demonstrated the ability to surface diversion concerns early without inundating staff with manual processes. This new patent reflects our novel approach to bolstering our customers’ diversion monitoring strategies.”

Protenus now holds more than a dozen granted U.S. patents covering various key aspects of patient privacy monitoring and drug diversion surveillance technologies, along with several other pending U.S. and foreign patent applications.

Any licensing inquiries or other questions about the Protenus patent portfolio should be directed to Amy Much, Protenus' General Counsel, at [email protected].

About Protenus

Protenus harnesses the power of AI to provide healthcare organizations with scalable risk-reduction solutions that drive the safest patient outcomes while protecting the reputation of the organizations. We are committed to innovation, determined to reduce risk, and focused on supporting our community of employees, customers, and ultimately, patients. Empowering healthcare to eliminate risk is at the heart of all we do. Founded in 2014, Protenus was awarded Best in KLAS for both patient privacy monitoring and drug diversion surveillance solutions two years in a row (2023-2024), is a three-time winner of Forbes’ America’s Best Startup Employers, is a Great Place to Work®-Certified company, was named one of 2021 CBInsights Digital Health 150, one of The Best Places to Work in Healthcare by Modern Healthcare, and one of the Best Places to Work in Baltimore by the Baltimore Business Journal and the Baltimore Sun. Learn more at Protenus.com and follow us on X (Twitter) @Protenus.

Contact Information:
Michelle Del Guercio
Chief Marketing Officer
[email protected]
(410) 995-8850


Original Source: Protenus Granted Sixth Patent for Drug Diversion Surveillance Technology

Related articles

Hard Rock International, Seminole Gaming, Royal Caribbean International and Celebrity Cruises Announce Global Partnership, Bringing Travel Benefits Across Land and Sea

The millions of combined members of the brands' casino rewards programs will enjoy reciprocal benefits through Unity by...

Aquaman and The Lost Kingdom: Is It Actually Bad Or Fine For What It Is?

https://www.youtube.com/watch?v=O1VcPTI1wZc Remember how the first Aquaman came out and was a colossal success? It really seemed like everything was...

Vista Point Financial Holdings, LLC Completes $333.98 Million Securitization Backed by Closed End Seconds

Securitization Backed by Nonagency Closed End Second Lien, Owner Occupied and Investor Mortgage Loans Vista Point Mortgage Logo ...

Could Coyote vs. Acme actually be released?

A spokesperson for Warner Bros. says reports of Coyote vs. Acme officially being shelved are “inaccurate.” Last Updated on...